| | Today’s Big News Sep 8, 2023 |
| | | By Annalee Armstrong Verge Genomics is adding AstraZeneca to its Big Pharma AI collection with a $42 million upfront deal to find new targets for rare neurodegenerative diseases. |
|
|
|
| By Nick Paul Taylor ILiAD Biotechnologies says it hit a homer in a whooping cough vaccine challenge trial. The biotech linked its nasal vaccine to protection against colonization by the pathogen, causing the phase 2b study to meet its primary endpoint in the per-protocol population. |
| By James Waldron The week after Otsuka Pharmaceutical made moves into the psychedelics space, the Japanese drugmaker has clinched a collaboration with Shape Therapeutics to develop intravitreally delivered adeno-associated viruses for ocular diseases. |
| By Helen Floersh Researchers have used stem cells to develop new human embryolike structures that model the earliest stages of human fetal development, even secreting hormones that turned a lab pregnancy test positive. |
| October 16-18, 2023 | Boston, MA Hear from leading experts as they share their experiences and insights covering drug development from the earliest stage of research to FDA approval. Register today & Save $200!
|
|
| By Max Bayer,Gabrielle Masson Diagnostic giant Illumina has found a new top boss following a tumultuous last few months marked by the departure of CEO Francis DeSouza, with Jacob Thaysen, Ph.D., now set to take over. |
| By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
| By Kevin Dunleavy Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios. |
| By Angus Liu Roche may not receive the FDA's decision on a subcutaneous version of its cancer immunotherapy Tecentriq on time thanks to the agency's requirement for changes to the drug's manufacturing process. |
| By Frank Diamond Inflation is likely making it harder for seniors to get the care they need, according to a survey from insurtech Alignment Health. |
| By Angus Liu Astellas has abandoned its challenge against the Inflation Reduction Act. Otsuka bought a Canadian psychedelic biotech. And Takeda is ordered to pay AbbVie nearly $480 million because of a manufacturing hiccup. And more. |
| Wednesday, September 13, 2023 | 12pm ET / 9am PT Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Join us to learn how to leverage an established lentiviral vector (LVV) process for accelerating drug product development. Register today.
|
|
| Whitepaper Access this insightful whitepaper to explore the role collaboration platform technology can play in helping address current industry challenges and to generate business value. Sponsored by: Zoom |
| Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| | |
|
